51
|
Vaccines against Botulism. Toxins (Basel) 2017; 9:toxins9090268. [PMID: 28869493 PMCID: PMC5618201 DOI: 10.3390/toxins9090268] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2017] [Revised: 08/30/2017] [Accepted: 08/30/2017] [Indexed: 12/16/2022] Open
Abstract
Botulinum neurotoxins (BoNT) cause the flaccid paralysis of botulism by inhibiting the release of acetylcholine from motor neurons. There are seven serotypes of BoNT (A-G), with limited therapies, and no FDA approved vaccine for botulism. An investigational formalin-inactivated penta-serotype-BoNT/A-E toxoid vaccine was used to vaccinate people who are at high risk of contracting botulism. However, this formalin-inactivated penta-serotype-BoNT/A-E toxoid vaccine was losing potency and was discontinued. This article reviews the different vaccines being developed to replace the discontinued toxoid vaccine. These vaccines include DNA-based, viral vector-based, and recombinant protein-based vaccines. DNA-based vaccines include plasmids or viral vectors containing the gene encoding one of the BoNT heavy chain receptor binding domains (HC). Viral vectors reviewed are adenovirus, influenza virus, rabies virus, Semliki Forest virus, and Venezuelan Equine Encephalitis virus. Among the potential recombinant protein vaccines reviewed are HC, light chain-heavy chain translocation domain, and chemically or genetically inactivated holotoxin.
Collapse
|
52
|
Evolution and spread of Venezuelan equine encephalitis complex alphavirus in the Americas. PLoS Negl Trop Dis 2017; 11:e0005693. [PMID: 28771475 PMCID: PMC5557581 DOI: 10.1371/journal.pntd.0005693] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2016] [Revised: 08/15/2017] [Accepted: 06/08/2017] [Indexed: 01/19/2023] Open
Abstract
Venezuelan equine encephalitis (VEE) complex alphaviruses are important re-emerging arboviruses that cause life-threatening disease in equids during epizootics as well as spillover human infections. We conducted a comprehensive analysis of VEE complex alphaviruses by sequencing the genomes of 94 strains and performing phylogenetic analyses of 130 isolates using complete open reading frames for the nonstructural and structural polyproteins. Our analyses confirmed purifying selection as a major mechanism influencing the evolution of these viruses as well as a confounding factor in molecular clock dating of ancestors. Times to most recent common ancestors (tMRCAs) could be robustly estimated only for the more recently diverged subtypes; the tMRCA of the ID/IAB/IC/II and IE clades of VEE virus (VEEV) were estimated at ca. 149–973 years ago. Evolution of the IE subtype has been characterized by a significant evolutionary shift from the rest of the VEEV complex, with an increase in structural protein substitutions that are unique to this group, possibly reflecting adaptation to its unique enzootic mosquito vector Culex (Melanoconion) taeniopus. Our inferred tree topologies suggest that VEEV is maintained primarily in situ, with only occasional spread to neighboring countries, probably reflecting the limited mobility of rodent hosts and mosquito vectors. The Venezuelan equine encephalitis (VEE) complex comprises a broadly distributed group of alphaviruses in the Americas that have the potential to emerge and cause severe disease. Historically, VEE complex viruses have caused recurring outbreaks of human and equine encephalitis in Central and South America as well as Mexico, with at least one outbreak resulting in movement of the virus to the southern United States. We present the most comprehensive phylogenetic analysis of complete genomic sequences of the most prominent member of the VEE complex, VEE virus (VEEV). We were able to identify the major forces influencing VEEV evolution, and using the inferred phylogenies we determined that VEEV evolves in geographically segregated lineages with enzootic transmission between rodents and mosquitoes apparently limiting its spread.
Collapse
|
53
|
|
54
|
Carrera JP, Díaz Y, Denis B, Barahona de Mosca I, Rodriguez D, Cedeño I, Arauz D, González P, Cerezo L, Moreno L, García L, Sáenz LE, Atencio MA, Rojas-Fermin E, Vizcaino F, Perez N, Moreno B, López-Vergès S, Valderrama A, Armién B. Unusual pattern of chikungunya virus epidemic in the Americas, the Panamanian experience. PLoS Negl Trop Dis 2017; 11:e0005338. [PMID: 28222127 PMCID: PMC5336303 DOI: 10.1371/journal.pntd.0005338] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 03/03/2017] [Accepted: 01/18/2017] [Indexed: 12/27/2022] Open
Abstract
Background Chikungunya virus (CHIKV) typically causes explosive epidemics of fever, rash and polyarthralgia after its introduction into naïve populations. Since its introduction in Panama in May of 2014, few autochthonous cases have been reported; most of them were found within limited outbreaks in Panama City in 2014 and Puerto Obaldia town, near the Caribbean border with Colombia in 2015. In order to confirm that Panama had few CHIKV cases compared with neighboring countries, we perform an epidemiological analysis of chikungunya cases reported from May 2014 to July 2015. Moreover, to understand this paucity of confirmed CHIKV cases, a vectorial analysis in the counties where these cases were reported was performed. Methods Chikungunya cases were identified at medical centers and notified to health authorities. Sera samples were analyzed at Gorgas Memorial Institute for viral RNA and CHIKV-specific antibody detection. Results A total of 413 suspected cases of CHIKV infections were reported, with incidence rates of 0.5 and 0.7 per 100,000 inhabitants in 2014 and 2015, respectively. During this period, 38.6% of CHIKV cases were autochthonous with rash and polyarthralgia as predominant symptoms. CHIKV and DENV incidence ratios were 1:306 and 1:34, respectively. A phylogenetic analysis of E1/E2 genomic segment indicates that the outbreak strains belong to the Asian genotype and cluster together with CHIKV isolates from other American countries during the same period. Statistical analysis of the National Vector Control program at the district level shows low and medium vector infestation level for most of the counties with CHIKV cases. This index was lower than for neighboring countries. Conclusions Previous training of clinical, laboratory and vector workers allowed a good caption and detection of the chikungunya cases and fast intervention. It is possible that low/medium vector infestation level could explain in part the paucity of chikungunya infections in Panama. Chikungunya virus (CHIKV) is a mosquito borne pathogen that causes fever with rash and arthralgia, which are often confused with Dengue virus (DENV) infections. It has been reported that when CHIKV colonizes regions without previous circulation, it generally results in explosive human epidemics. In Panama, the first CHIKV infections were detected in May 2014. However, unlike many countries in the Americas, Panama presented with few autochthonous cases during the outbreak. In this study, we investigated the likely reason for the paucity of cases. Low vector infestation level, along with the surveillance programs, preparedness and early outbreak response possibly influenced the low number of cases observed during the Panamanian CHIKV outbreak.
Collapse
Affiliation(s)
- Jean-Paul Carrera
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
- Department of Pre-clinical Sciences, School of Medicine, Columbus University; Panama City, Panama
| | - Yamilka Díaz
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Bernardino Denis
- Department of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | | | - Dennys Rodriguez
- National Department of Epidemiology, Ministry of Health; Panama City, Panama
| | - Israel Cedeño
- National Department of Epidemiology, Ministry of Health; Panama City, Panama
| | - Dimelza Arauz
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Publio González
- Department of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Lizbeth Cerezo
- National Department of Epidemiology, Ministry of Health; Panama City, Panama
| | - Lourdes Moreno
- National Department of Epidemiology, Ministry of Health; Panama City, Panama
| | - Lourdes García
- National Department of Epidemiology, Ministry of Health; Panama City, Panama
| | - Lisseth E. Sáenz
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - María Aneth Atencio
- Immunovirology section, Public Health Reference Laboratory, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Eddy Rojas-Fermin
- Department of Pre-clinical Sciences, School of Medicine, Columbus University; Panama City, Panama
| | - Fernando Vizcaino
- Vector-Control National Department, Ministry of Health; Panama City, Panama
| | | | - Brechla Moreno
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Sandra López-Vergès
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Anayansi Valderrama
- Department of Research in Medical Entomology, Gorgas Memorial Institute of Health Studies; Panama City, Panama
| | - Blas Armién
- Department of Research in Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies; Panama City, Panama
- Research Direction, Universidad Interamericana de Panama; Panama City, Panama
- * E-mail:
| |
Collapse
|
55
|
Erwin-Cohen RA, Porter AI, Pittman PR, Rossi CA, DaSilva L. Human transcriptome response to immunization with live-attenuated Venezuelan equine encephalitis virus vaccine (TC-83): Analysis of whole blood. Hum Vaccin Immunother 2016; 13:169-179. [PMID: 27870591 PMCID: PMC5287313 DOI: 10.1080/21645515.2016.1227900] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Venezuelan equine encephalitis virus (VEEV) is an important human and animal alphavirus pathogen transmitted by mosquitoes. The virus is endemic in Central and South America, but has also caused equine outbreaks in southwestern areas of the United States. In an effort to better understand the molecular mechanisms of the development of immunity to this important pathogen, we performed transcriptional analysis from whole, unfractionated human blood of patients who had been immunized with the live-attenuated vaccine strain of VEEV, TC-83. We compared changes in the transcriptome between naïve individuals who were mock vaccinated with saline to responses of individuals who received TC-83. Significant transcriptional changes were noted at days 2, 7, and 14 following vaccination. The top canonical pathways revealed at early and intermediate time points (days 2 and 7) included the involvement of the classic interferon response, interferon-response factors, activation of pattern recognition receptors, and engagement of the inflammasome. By day 14, the top canonical pathways included oxidative phosphorylation, the protein ubiquitination pathway, natural killer cell signaling, and B-cell development. Biomarkers were identified that differentiate between vaccinees and control subjects, at early, intermediate, and late stages of the development of immunity as well as markers which were common to all 3 stages following vaccination but distinct from the sham-vaccinated control subjects. The study represents a novel examination of molecular processes that lead to the development of immunity against VEEV in humans and which may be of value as diagnostic targets, to enhance modern vaccine design, or molecular correlates of protection.
Collapse
Affiliation(s)
- Rebecca A Erwin-Cohen
- a Virology Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA
| | - Aimee I Porter
- a Virology Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA
| | - Phillip R Pittman
- b Division of Medicine, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA
| | - Cynthia A Rossi
- c Diagnostics Systems Division, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA
| | - Luis DaSilva
- d Center for Aerobiological Sciences, United States Army Military Research Institute of Infectious Diseases (USAMRIID) , Frederick , MD , USA
| |
Collapse
|
56
|
Vittor AY, Armien B, Gonzalez P, Carrera JP, Dominguez C, Valderrama A, Glass GE, Beltran D, Cisneros J, Wang E, Castillo A, Moreno B, Weaver SC. Epidemiology of Emergent Madariaga Encephalitis in a Region with Endemic Venezuelan Equine Encephalitis: Initial Host Studies and Human Cross-Sectional Study in Darien, Panama. PLoS Negl Trop Dis 2016; 10:e0004554. [PMID: 27101567 PMCID: PMC4839771 DOI: 10.1371/journal.pntd.0004554] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2015] [Accepted: 02/26/2016] [Indexed: 11/18/2022] Open
Abstract
Background Neurotropic arboviral infections are an important cause of encephalitis. A zoonotic, vector-borne alphavirus, Madariaga virus (MADV; formerly known as South American eastern equine encephalitis virus), caused its first documented human outbreak in 2010 in Darien, Panama, where the genetically similar Venezuelan equine encephalitis virus (VEEV) is endemic. We report the results of a seroprevalence survey of animals and humans, illustrating contrasting features of MADV and VEEV ecology and epidemiology. Methods Small mammals were trapped in 42 sites in Darien, Panama, using Sherman traps, Tomahawk traps, and mist nets for bats. Blood was tested for the presence of neutralizing antibodies to MADV and VEEV. In addition, bird sera collected in 2007 in Chagres, Panama, were tested for MADV and VEEV neutralizing antibodies. Viremia was ascertained by RT-PCR. Human exposure to these two viruses was determined by IgG ELISA, followed by plaque reduction neutralization tests. To identify relevant risk factors for MADV or VEEV exposure, logistic regression analysis was performed, and the most parsimonious model was selected based on the Akaike information criterion. Results The animal survey yielded 32 bats (16 species), 556 rodents (12 species), and 20 opossums (4 species). The short-tailed cane mouse (Zygodontomys brevicauda) found abundantly in pasture and farms, had the highest MADV seroprevalence (8.3%). For VEEV, the shrub and forest-dwelling long-whiskered rice rat (Transandinomys bolivaris) had the highest seroprevalence (19.0%). Viremia was detected in one animal (Z. brevicauda). Of the 159 bird sera (50 species) tested, none were positive for either virus. In humans (n = 770), neutralizing antibodies to MADV and VEEV were present in 4.8% and 31.5%, respectively. MADV seropositivity was positively associated with cattle ranching, farming, and fishing. Having VEEV antibodies and shrubs near the house diminished risk. Age, forest work, farming and fishing were risk factors for VEEV, while having MADV antibodies, glazed windows, waste pick-up and piped water were protective. Conclusion Our findings suggest that the short-tailed cane mouse and the long-whiskered rice rat serve as hosts for MADV and VEEV, respectively. The preferred habitat of these rodent species coincides with areas associated with human infection risk. Our findings also indicate that MADV emerged recently in humans, and that the transmission cycles of these two sympatric alphaviruses differ spatially and in host utilization. Arthropod-borne viruses are important causes of encephalitis. In 2010, the first documented human outbreak of the mosquito-borne, zoonotic Madariaga virus (MADV) occurred in the Darien region of Panama. Neither its epidemiology nor its transmission cycle is understood. In this study, the authors searched for possible animal hosts of this virus, and sought to describe its epidemiology. They contrast the findings with those for Venezuelan equine encephalitis virus (VEEV), an endemic, genetically similar virus. Zygodontomys brevicauda, the short-tailed cane mouse, had the highest seroprevalence for MADV. This rodent species is most often found in pasture and farm land. Indeed, the risk factors for human MADV exposure were cattle ranching and farming. The animal with highest seroprevalence for VEEV, the long-whiskered rice rat (Transandinomys bolivaris), commonly occurs in forest, and the epidemiological risk factors included working in the forest. Farming and fishing were risk factors for exposure to both viruses, and having antibodies to one virus diminished the risk of being positive for the other. Increasing prevalence with age was seen for VEEV, confirming that VEEV is endemic in the region. This association was absent for MADV, suggesting that this virus emerged recently to infect humans.
Collapse
Affiliation(s)
- Amy Y. Vittor
- Department of Medicine, University of Florida, Gainesville, Florida, United States of America
- Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
- * E-mail:
| | - Blas Armien
- Department of Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama
- Universidad Interamericana de Panama, Panama City, Panama
| | - Publio Gonzalez
- Department of Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Jean-Paul Carrera
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Claudia Dominguez
- Department of Emerging and Zoonotic Diseases, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Anayansi Valderrama
- Department of Medical Entomology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Greg E. Glass
- Department of Geography, University of Florida, Gainesville, Florida, United States of America
| | - Davis Beltran
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Julio Cisneros
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Eryu Wang
- Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Alex Castillo
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Brechla Moreno
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | - Scott C. Weaver
- Institute for Human Infections and Immunity and Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
| |
Collapse
|
57
|
Eastwood G, Loaiza JR, Pongsiri MJ, Sanjur OI, Pecor JE, Auguste AJ, Kramer LD. Enzootic Arbovirus Surveillance in Forest Habitat and Phylogenetic Characterization of Novel Isolates of Gamboa Virus in Panama. Am J Trop Med Hyg 2016; 94:786-93. [PMID: 26834200 PMCID: PMC4824219 DOI: 10.4269/ajtmh.15-0445] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 11/25/2015] [Indexed: 11/07/2022] Open
Abstract
Landscape changes occurring in Panama, a country whose geographic location and climate have historically supported arbovirus transmission, prompted the hypothesis that arbovirus prevalence increases with degradation of tropical forest habitats. Investigations at four variably degraded sites revealed a diverse array of potential mosquito vectors, several of which are known vectors of arbovirus pathogens. Overall, 675 pools consisting of 25,787 mosquitoes and representing 29 species from nine genera (collected at ground and canopy height across all habitats) were screened for cytopathic viruses on Vero cells. We detected four isolates of Gamboa virus (family:Bunyaviridae; genus:Orthobunyavirus) from pools of Aedeomyia squamipennis captured at canopy level in November 2012. Phylogenetic characterization of complete genome sequences shows the new isolates to be closely related to each other with strong evidence of reassortment among the M segment of Panamanian Gamboa isolates and several other viruses of this group. At the site yielding viruses, Soberanía National Park in central Panama, 18 mosquito species were identified, and the predominant taxa included A. squamipennis,Coquillettidia nigricans, and Mansonia titillans.
Collapse
Affiliation(s)
- Gillian Eastwood
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - Jose R Loaiza
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - Montira J Pongsiri
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - Oris I Sanjur
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - James E Pecor
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - Albert J Auguste
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| | - Laura D Kramer
- Wadsworth Center, New York State Department of Health, Slingerlands, New York; Instituto de Investigaciones Científicas y Servicios de Alta Tecnología (INDICASAT), Ciudad del Saber, República de Panamá; U.S. Environmental Protection Agency, Washington, District of Columbia; Smithsonian Tropical Research Institute, Panama City, Republic of Panama; Walter Reed Biosystematics Unit, Suitland, Maryland; Department of Pathology, University of Texas Medical Branch, Galveston, Texas
| |
Collapse
|
58
|
Hontz RD, Guevara C, Halsey ES, Silvas J, Santiago FW, Widen SG, Wood TG, Casanova W, Vasilakis N, Watts DM, Kochel TJ, Ebihara H, Aguilar PV. Itaya virus, a Novel Orthobunyavirus Associated with Human Febrile Illness, Peru. Emerg Infect Dis 2016; 21:781-8. [PMID: 25898901 PMCID: PMC4412221 DOI: 10.3201/eid2105.141368] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Analysis of uncharacterized bunyavirus isolates identified a possible reassortant virus. Our genetic analyses of uncharacterized bunyaviruses isolated in Peru identified a possible reassortant virus containing small and large gene segment sequences closely related to the Caraparu virus and a medium gene segment sequence potentially derived from an unidentified group C orthobunyavirus. Neutralization tests confirmed serologic distinction among the newly identified virus and the prototype and Caraparu strains. This virus, named Itaya, was isolated in 1999 and 2006 from febrile patients in the cities of Iquitos and Yurimaguas in Peru. The geographic distance between the 2 cases suggests that the Itaya virus could be widely distributed throughout the Amazon basin in northeastern Peru. Identification of a new Orthobunyavirus species that causes febrile disease in humans reinforces the need to expand viral disease surveillance in tropical regions of South America.
Collapse
|
59
|
mRNA Capping by Venezuelan Equine Encephalitis Virus nsP1: Functional Characterization and Implications for Antiviral Research. J Virol 2015; 89:8292-303. [PMID: 26041283 DOI: 10.1128/jvi.00599-15] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2015] [Accepted: 05/19/2015] [Indexed: 12/26/2022] Open
Abstract
UNLABELLED Alphaviruses are known to possess a unique viral mRNA capping mechanism involving the viral nonstructural protein nsP1. This enzyme harbors methyltransferase (MTase) and nsP1 guanylylation (GT) activities catalyzing the transfer of the methyl group from S-adenosylmethionine (AdoMet) to the N7 position of a GTP molecule followed by the formation of an m(7)GMP-nsP1 adduct. Subsequent transfer of m(7)GMP onto the 5' end of the viral mRNA has not been demonstrated in vitro yet. Here we report the biochemical characterization of Venezuelan equine encephalitis virus (VEEV) nsP1. We have developed enzymatic assays uncoupling the different reactions steps catalyzed by nsP1. The MTase and GT reaction activities were followed using a nonhydrolyzable GTP (GIDP) substrate and an original Western blot assay using anti-m3G/m(7)G-cap monoclonal antibody, respectively. The GT reaction is stimulated by S-adenosyl-l-homocysteine (Ado-Hcy), the product of the preceding MTase reaction, and metallic ions. The covalent linking between nsP1 and m(7)GMP involves a phosphamide bond between the nucleotide and a histidine residue. Final guanylyltransfer onto RNA was observed for the first time with an alphavirus nsP1 using a 5'-diphosphate RNA oligonucleotide whose sequence corresponds to the 5' end of the viral genome. Alanine scanning mutagenesis of residues H37, H45, D63, E118, Y285, D354, R365, N369, and N375 revealed their respective roles in MT and GT reactions. Finally, the inhibitory effects of sinefungin, aurintricarboxylic acid (ATA), and ribavirin triphosphate on MTase and capping reactions were investigated, providing possible avenues for antiviral research. IMPORTANCE Emergence or reemergence of alphaviruses represents a serious health concern, and the elucidation of their replication mechanisms is a prerequisite for the development of specific inhibitors targeting viral enzymes. In particular, alphaviruses are able, through an original reaction sequence, to add to their mRNA a cap required for their protection against cellular nucleases and initiation of viral proteins translation. In this study, the capping of a 5' diphosphate synthetic RNA mimicking the 5' end of an alphavirus mRNA was observed in vitro for the first time. The different steps for this capping are performed by the nonstructural protein 1 (nsP1). Reference compounds known to target the viral capping inhibited nsP1 enzymatic functions, highlighting the value of this enzyme in antiviral development.
Collapse
|
60
|
Rossi SL, Russell-Lodrigue KE, Killeen SZ, Wang E, Leal G, Bergren NA, Vinet-Oliphant H, Weaver SC, Roy CJ. IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge. PLoS Negl Trop Dis 2015; 9:e0003797. [PMID: 26020513 PMCID: PMC4447396 DOI: 10.1371/journal.pntd.0003797] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 04/28/2015] [Indexed: 11/26/2022] Open
Abstract
Venezuelan equine encephalitis virus (VEEV) is an arbovirus endemic to the Americas that is responsible for severe, sometimes fatal, disease in humans and horses. We previously described an IRES-based VEE vaccine candidate based up the IE serotype that offers complete protection against a lethal subtype IE VEEV challenge in mice. Here we demonstrate the IRES-based vaccine’s ability to protect against febrile disease in cynomolgus macaques. Vaccination was well tolerated and elicited robust neutralizing antibody titers noticed as early as day 14. Moreover, complete protection from disease characterized by absence of viremia and characteristic fever following aerosolized IE VEEV challenge was observed in all vaccinees compared to control animals, which developed clinical disease. Together, these results highlight the safety and efficacy of IRES-based VEEV vaccine to protect against an endemic, pathogenic VEEV IE serotype. Venezuelan equine encephalitis virus (VEEV) is a mosquito-borne arbovirus endemic to the Americas that affects a wide range of equids and humans. Vaccination has been one of the strategies to combat spread of disease in areas with high rates incidence of VEEV, although existing vaccines have proven less than effective against genetically diverse serotypes. In addition to being a natural vectorborne threat, VEEV is considered a biological threat agent that could be used as a weapon. We evaluated a new Internal Ribosome Entry Site (IRES)-containing chimeric viral vaccine using an advanced nonhuman primate model of VEEV infection. Vaccinated animals showed robust humoral immune responses to a single prime immunization with IE VEEV/IRES vaccine. The vaccine protected against an aerosolized IE (68U201) challenge, with vaccinees showing no blood viremia or development of febrile disease, including no pyrexia associated with VEEV infection. This vaccine product has shown efficacy against serotype-specific challenge model and provides enabling data as the basis for future clinical development.
Collapse
Affiliation(s)
- Shannan L. Rossi
- Institute of Human Infection and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Kasi E. Russell-Lodrigue
- Divisions of Veterinary Medicine and Microbiology, Tulane National Primate Research Center, Covington, Louisiana, United States of America
| | - Stephanie Z. Killeen
- Divisions of Veterinary Medicine and Microbiology, Tulane National Primate Research Center, Covington, Louisiana, United States of America
| | - Eryu Wang
- Institute of Human Infection and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Grace Leal
- Institute of Human Infection and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Nicholas A. Bergren
- Institute of Human Infection and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Heather Vinet-Oliphant
- Divisions of Veterinary Medicine and Microbiology, Tulane National Primate Research Center, Covington, Louisiana, United States of America
| | - Scott C. Weaver
- Institute of Human Infection and Immunity, Sealy Center for Vaccine Development and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
- * E-mail:
| | - Chad J. Roy
- Divisions of Veterinary Medicine and Microbiology, Tulane National Primate Research Center, Covington, Louisiana, United States of America
- Department of Microbiology and Immunology, Tulane School of Medicine, New Orleans, Louisiana, United States of America
| |
Collapse
|
61
|
Esteve-Gassent MD, Pérez de León AA, Romero-Salas D, Feria-Arroyo TP, Patino R, Castro-Arellano I, Gordillo-Pérez G, Auclair A, Goolsby J, Rodriguez-Vivas RI, Estrada-Franco JG. Pathogenic Landscape of Transboundary Zoonotic Diseases in the Mexico-US Border Along the Rio Grande. Front Public Health 2014; 2:177. [PMID: 25453027 PMCID: PMC4233934 DOI: 10.3389/fpubh.2014.00177] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2014] [Accepted: 09/19/2014] [Indexed: 01/11/2023] Open
Abstract
Transboundary zoonotic diseases, several of which are vector borne, can maintain a dynamic focus and have pathogens circulating in geographic regions encircling multiple geopolitical boundaries. Global change is intensifying transboundary problems, including the spatial variation of the risk and incidence of zoonotic diseases. The complexity of these challenges can be greater in areas where rivers delineate international boundaries and encompass transitions between ecozones. The Rio Grande serves as a natural border between the US State of Texas and the Mexican States of Chihuahua, Coahuila, Nuevo León, and Tamaulipas. Not only do millions of people live in this transboundary region, but also a substantial amount of goods and people pass through it everyday. Moreover, it occurs over a region that functions as a corridor for animal migrations, and thus links the Neotropic and Nearctic biogeographic zones, with the latter being a known foci of zoonotic diseases. However, the pathogenic landscape of important zoonotic diseases in the south Texas-Mexico transboundary region remains to be fully understood. An international perspective on the interplay between disease systems, ecosystem processes, land use, and human behaviors is applied here to analyze landscape and spatial features of Venezuelan equine encephalitis, Hantavirus disease, Lyme Borreliosis, Leptospirosis, Bartonellosis, Chagas disease, human Babesiosis, and Leishmaniasis. Surveillance systems following the One Health approach with a regional perspective will help identifying opportunities to mitigate the health burden of those diseases on human and animal populations. It is proposed that the Mexico-US border along the Rio Grande region be viewed as a continuum landscape where zoonotic pathogens circulate regardless of national borders.
Collapse
Affiliation(s)
- Maria Dolores Esteve-Gassent
- Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, USA
| | | | - Dora Romero-Salas
- Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, México
| | | | - Ramiro Patino
- Department of Biology, University of Texas-Pan American, Edinburg, TX, USA
| | - Ivan Castro-Arellano
- Department of Biology, College of Science and Engineering, Texas State University, San Marcos, TX, USA
| | - Guadalupe Gordillo-Pérez
- Unidad de Investigación en Enfermedades Infecciosas, Centro Médico Nacional SXXI, IMSS, Distrito Federal, México
| | - Allan Auclair
- Environmental Risk Analysis Systems, Policy and Program Development, Animal and Plant Health Inspection Service, United States Department of Agriculture, Riverdale, MD, USA
| | - John Goolsby
- Cattle Fever Tick Research Laboratory, United States Department of Agriculture, Agricultural Research Service, Edinburg, TX, USA
| | - Roger Ivan Rodriguez-Vivas
- Facultad de Medicina Veterinaria y Zootecnia, Cuerpo Académico de Salud Animal, Universidad Autónoma de Yucatán, Mérida, México
| | - Jose Guillermo Estrada-Franco
- Facultad de Medicina Veterinaria Zootecnia, Centro de Investigaciones y Estudios Avanzados en Salud Animal, Universidad Autónoma del Estado de México, Toluca, México
| |
Collapse
|
62
|
Chung DH, Jonsson CB, Tower NA, Chu YK, Sahin E, Golden JE, Noah JW, Schroeder CE, Sotsky JB, Sosa MI, Cramer DE, McKellip SN, Rasmussen L, White EL, Schmaljohn CS, Julander JG, Smith JM, Filone CM, Connor JH, Sakurai Y, Davey RA. Discovery of a novel compound with anti-venezuelan equine encephalitis virus activity that targets the nonstructural protein 2. PLoS Pathog 2014; 10:e1004213. [PMID: 24967809 PMCID: PMC4072787 DOI: 10.1371/journal.ppat.1004213] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2013] [Accepted: 05/13/2014] [Indexed: 12/27/2022] Open
Abstract
Alphaviruses present serious health threats as emerging and re-emerging viruses. Venezuelan equine encephalitis virus (VEEV), a New World alphavirus, can cause encephalitis in humans and horses, but there are no therapeutics for treatment. To date, compounds reported as anti-VEEV or anti-alphavirus inhibitors have shown moderate activity. To discover new classes of anti-VEEV inhibitors with novel viral targets, we used a high-throughput screen based on the measurement of cell protection from live VEEV TC-83-induced cytopathic effect to screen a 340,000 compound library. Of those, we identified five novel anti-VEEV compounds and chose a quinazolinone compound, CID15997213 (IC50 = 0.84 µM), for further characterization. The antiviral effect of CID15997213 was alphavirus-specific, inhibiting VEEV and Western equine encephalitis virus, but not Eastern equine encephalitis virus. In vitro assays confirmed inhibition of viral RNA, protein, and progeny synthesis. No antiviral activity was detected against a select group of RNA viruses. We found mutations conferring the resistance to the compound in the N-terminal domain of nsP2 and confirmed the target residues using a reverse genetic approach. Time of addition studies showed that the compound inhibits the middle stage of replication when viral genome replication is most active. In mice, the compound showed complete protection from lethal VEEV disease at 50 mg/kg/day. Collectively, these results reveal a potent anti-VEEV compound that uniquely targets the viral nsP2 N-terminal domain. While the function of nsP2 has yet to be characterized, our studies suggest that the protein might play a critical role in viral replication, and further, may represent an innovative opportunity to develop therapeutic interventions for alphavirus infection. Alphaviruses occur worldwide, causing significant diseases such as encephalitis or arthritis in humans and animals. In addition, some alphaviruses, such as VEEV, pose a biothreat due to their high infectivity and lack of available treatments. To discover small molecule inhibitors with lead development potential, we used a cell-based assay to screen 348,140 compounds for inhibition of a VEEV-induced cytopathic effect. The screen revealed a scaffold with high inhibitory VEEV cellular potency and low cytotoxicity liability. While most previously reported anti-alphavirus compounds inhibit host proteins, evidence supported that this scaffold targeted the VEEV nsP2 protein, and that inhibition was associated with viral replication. Interestingly, compound resistance studies with VEEV mapped activity to the N-terminal domain of nsP2, to which no known function has been attributed. Ultimately, this discovery has delivered a small molecule-derived class of potent VEEV inhibitors whose activity is coupled to the nsP2 viral protein, a novel target with a previously unestablished biological role that is now implicated in viral replication.
Collapse
Affiliation(s)
- Dong-Hoon Chung
- Departments of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, United States of America
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
- * E-mail:
| | - Colleen B. Jonsson
- Departments of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, United States of America
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky, United States of America
| | - Nichole A. Tower
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - Yong-Kyu Chu
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
| | - Ergin Sahin
- Departments of Microbiology and Immunology, University of Louisville, Louisville, Kentucky, United States of America
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
| | - Jennifer E. Golden
- University of Kansas Specialized Chemistry Center, Lawrence, Kansas, United States of America
| | - James W. Noah
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - Chad E. Schroeder
- University of Kansas Specialized Chemistry Center, Lawrence, Kansas, United States of America
| | - Julie B. Sotsky
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
| | - Melinda I. Sosa
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - Daniel E. Cramer
- Center for Predictive Medicine for Biodefense and Emerging Infectious Diseases, University of Louisville, Louisville, Kentucky, United States of America
| | - Sara N. McKellip
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - Lynn Rasmussen
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - E. Lucile White
- Drug Discovery Department, Southern Research Institute, Birmingham, Alabama, United States of America
| | - Connie S. Schmaljohn
- The United States Army Medical Research Institute for Infectious Diseases, Ft. Detrick, Maryland, United States of America
| | - Justin G. Julander
- Institute for Antiviral Research, Utah State University, Logan, Utah, United States of America
| | - Jeffrey M. Smith
- The United States Army Medical Research Institute for Infectious Diseases, Ft. Detrick, Maryland, United States of America
| | | | - John H. Connor
- Boston University, Boston, Massachusetts, United States of America
| | - Yasuteru Sakurai
- Texas Biomedical Research Institute, San Antonio, Texas, United States of America
| | - Robert A. Davey
- Texas Biomedical Research Institute, San Antonio, Texas, United States of America
| |
Collapse
|
63
|
Shafagati N, Patanarut A, Luchini A, Lundberg L, Bailey C, Petricoin E, Liotta L, Narayanan A, Lepene B, Kehn-Hall K. The use of Nanotrap particles for biodefense and emerging infectious disease diagnostics. Pathog Dis 2014; 71:164-76. [PMID: 24449537 PMCID: PMC7108521 DOI: 10.1111/2049-632x.12136] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2013] [Revised: 01/07/2014] [Accepted: 01/07/2014] [Indexed: 11/28/2022] Open
Abstract
Detection of early infectious disease may be challenging due to the low copy number of organisms present. To overcome this limitation and rapidly measure low concentrations of the pathogen, we developed a novel technology: Nanotrap particles, which are designed to capture, concentrate, and protect biomarkers from complex biofluids. Nanotrap particles are thermoresponsive hydrogels that are capable of antigen capture through the coupling of affinity baits to the particles. Here, we describe recent findings demonstrating that Nanotrap particles are able to capture live infectious virus, viral RNA, and viral proteins. Capture is possible even in complex mixtures such as serum and allows the concentration and protection of these analytes, providing increased performance of downstream assays. The Nanotrap particles are a versatile sample preparation technology that has far reaching implications for biomarker discovery and diagnostic assays.
Collapse
Affiliation(s)
- Nazly Shafagati
- National Center for Biodefense and Infectious Diseases, School of Systems Biology, George Mason University, Manassas, VA, USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
64
|
Go YY, Balasuriya UBR, Lee CK. Zoonotic encephalitides caused by arboviruses: transmission and epidemiology of alphaviruses and flaviviruses. Clin Exp Vaccine Res 2013; 3:58-77. [PMID: 24427764 PMCID: PMC3890452 DOI: 10.7774/cevr.2014.3.1.58] [Citation(s) in RCA: 127] [Impact Index Per Article: 11.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2013] [Revised: 10/03/2013] [Accepted: 10/20/2013] [Indexed: 12/29/2022] Open
Abstract
In this review, we mainly focus on zoonotic encephalitides caused by arthropod-borne viruses (arboviruses) of the families Flaviviridae (genus Flavivirus) and Togaviridae (genus Alphavirus) that are important in both humans and domestic animals. Specifically, we will focus on alphaviruses (Eastern equine encephalitis virus, Western equine encephalitis virus, Venezuelan equine encephalitis virus) and flaviviruses (Japanese encephalitis virus and West Nile virus). Most of these viruses were originally found in tropical regions such as Africa and South America or in some regions in Asia. However, they have dispersed widely and currently cause diseases around the world. Global warming, increasing urbanization and population size in tropical regions, faster transportation and rapid spread of arthropod vectors contribute in continuous spreading of arboviruses into new geographic areas causing reemerging or resurging diseases. Most of the reemerging arboviruses also have emerged as zoonotic disease agents and created major public health issues and disease epidemics.
Collapse
Affiliation(s)
- Yun Young Go
- Virus Research and Testing Group, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, Daejeon, Korea
| | - Udeni B R Balasuriya
- Maxwell H. Gluck Equine Research Center, Department of Veterinary Science, College of Agriculture, Food and Environment, University of Kentucky, Lexington, KY, USA. ; Department of Microbiology, Immunology and Molecular Genetics, College of Medicine, University of Kentucky, Lexington, KY, USA
| | - Chong-Kyo Lee
- Virus Research and Testing Group, Division of Drug Discovery Research, Korea Research Institute of Chemical Technology, Daejeon, Korea
| |
Collapse
|
65
|
Pisano MB, Oria G, Beskow G, Aguilar J, Konigheim B, Cacace ML, Aguirre L, Stein M, Contigiani MS. Venezuelan equine encephalitis viruses (VEEV) in Argentina: serological evidence of human infection. PLoS Negl Trop Dis 2013; 7:e2551. [PMID: 24349588 PMCID: PMC3861189 DOI: 10.1371/journal.pntd.0002551] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2013] [Accepted: 10/07/2013] [Indexed: 11/19/2022] Open
Abstract
Venezuelan equine encephalitis viruses (VEEV) are responsible for human diseases in the Americas, producing severe or mild illness with symptoms indistinguishable from dengue and other arboviral diseases. For this reason, many cases remain without certain diagnosis. Seroprevalence studies for VEEV subtypes IAB, ID, IF (Mosso das Pedras virus; MDPV), IV (Pixuna virus; PIXV) and VI (Rio Negro virus; RNV) were conducted in persons from Northern provinces of Argentina: Salta, Chaco and Corrientes, using plaque reduction neutralization test (PRNT). RNV was detected in all studied provinces. Chaco presented the highest prevalence of this virus (14.1%). Antibodies against VEEV IAB and -for the first time- against MDPV and PIXV were also detected in Chaco province. In Corrientes, seroprevalence against RNV was 1.3% in the pediatric population, indicating recent infections. In Salta, this was the first investigation of VEEV members, and antibodies against RNV and PIXV were detected. These results provide evidence of circulation of many VEE viruses in Northern Argentina, showing that surveillance of these infectious agents should be intensified. Venezuelan equine encephalitis viruses (VEEV) are responsible for human diseases in the Americas. They produce severe or mild illnesses with symptoms indistinguishable from dengue and other arboviral diseases; for this reason, many cases remain undiagnosed. We detected neutralizing antibodies (NTAbs) against VEEV IAB, VEEV ID, MDPV (VEEV subtype IF), PIXV (VEEV subtype IV) and RNV (VEEV subtype VI) in human serum samples of Northern provinces of Argentina. Chaco province showed presence of NTAbs against VEEV IAB, MDPV, PIXV and RNV. In Corrientes province, we detected NTAbs against RNV in a pediatric population. NTAbs against PIXV and RNV were also detected in Salta province. These findings demonstrated the circulation of many VEEV strains in Northern Argentina and underscore the need for surveillance of dengue like illness in this region.
Collapse
Affiliation(s)
- María Belén Pisano
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enfermera Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
- * E-mail:
| | - Griselda Oria
- Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Chaco, Argentina
| | - Geraldine Beskow
- Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Chaco, Argentina
| | - Javier Aguilar
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enfermera Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | - Brenda Konigheim
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enfermera Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| | | | - Luis Aguirre
- Hospital Dante Tardelli, Pampa del Indio, Chaco, Argentina
| | - Marina Stein
- Instituto de Medicina Regional, Universidad Nacional del Nordeste, Resistencia, Chaco, Argentina
| | - Marta Silvia Contigiani
- Instituto de Virología “Dr. J. M. Vanella”, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Enfermera Gordillo Gómez s/n, Ciudad Universitaria, Córdoba, Argentina
| |
Collapse
|
66
|
Sullivan-Pyke CS, Nurudeen SK, Grossman LC, Sauer MV, Douglas NC. Fertility treatment options for HIV-infected individuals. Future Virol 2013. [DOI: 10.2217/fvl.13.101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Many HIV-serodiscordant couples desire children and physician-assisted techniques can help individuals achieve pregnancy while reducing the risk of seroconversion in their seronegative partner. For HIV-seropositive males, sperm washing with intrauterine insemination (SW-IUI) was introduced in Europe in the early 1990s, while in the USA in vitro fertilization with intracytoplasmic sperm injection (IVF-ICSI) has been primarily used to reduce the risk of viral transmission. When properly applied to well-selected populations, no seroconversion has been reported with either of these methods. Within the last 5 years, randomized controlled studies have demonstrated the efficacy of daily pre-exposure prophylaxis in reducing the risk of seroconversion in couples having intercourse when an HIV-seropositive male has undetectable viral loads. In both the USA and Europe, favorable reproductive outcomes have been reported for HIV-seropositive females undergoing IUI and IVF-ICSI. Herein, we review the use of various contemporary reproductive techniques available to HIV-serodiscordant couples interested in having children, including new data on cumulative clinical pregnancy rates and cumulative live-birth rates after IVF-ICSI for male serodiscordant couples. We conclude by proposing that pre-exposure prophylaxis with SW-IUI may be a safe, economical and effective alternative for achieving pregnancy in well-selected, monogamous HIV-serodiscordant couples where the male partner is seropositive.
Collapse
Affiliation(s)
- Chantae S Sullivan-Pyke
- Columbia University, Department of OB-GYN, Division of Reproductive Endocrinology & Infertility, 622 W 168th Street, PH-16, New York, NY 10032, USA
| | - Sahadat K Nurudeen
- Columbia University, Department of OB-GYN, Division of Reproductive Endocrinology & Infertility, 622 W 168th Street, PH-16, New York, NY 10032, USA
| | - Lisa C Grossman
- Columbia University, Department of OB-GYN, Division of Reproductive Endocrinology & Infertility, 622 W 168th Street, PH-16, New York, NY 10032, USA
| | - Mark V Sauer
- Columbia University, Department of OB-GYN, Division of Reproductive Endocrinology & Infertility, 622 W 168th Street, PH-16, New York, NY 10032, USA
| | - Nataki C Douglas
- Columbia University, Department of OB-GYN, Division of Reproductive Endocrinology & Infertility, 622 W 168th Street, PH-16, New York, NY 10032, USA
| |
Collapse
|
67
|
Monath TP. Vaccines against diseases transmitted from animals to humans: a one health paradigm. Vaccine 2013; 31:5321-38. [PMID: 24060567 PMCID: PMC7130581 DOI: 10.1016/j.vaccine.2013.09.029] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2013] [Revised: 09/08/2013] [Accepted: 09/16/2013] [Indexed: 10/28/2022]
Abstract
This review focuses on the immunization of animals as a means of preventing human diseases (zoonoses). Three frameworks for the use of vaccines in this context are described, and examples are provided of successes and failures. Framework I vaccines are used for protection of humans and economically valuable animals, where neither plays a role in the transmission cycle. The benefit of collaborations between animal health and human health industries and regulators in developing such products is discussed, and one example (West Nile vaccine) of a single product developed for use in animals and humans is described. Framework II vaccines are indicated for domesticated animals as a means of preventing disease in both animals and humans. The agents of concern are transmitted directly or indirectly (e.g. via arthropod vectors) from animals to humans. A number of examples of the use of Framework II vaccines are provided, e.g. against brucellosis, Escherichia coli O157, rabies, Rift Valley fever, Venezuelan equine encephalitis, and Hendra virus. Framework III vaccines are used to immunize wild animals as a means of preventing transmission of disease agents to humans and domesticated animals. Examples are reservoir-targeted, oral bait rabies, Mycobacterium bovis and Lyme disease vaccines. Given the speed and lost cost of veterinary vaccine development, some interventions based on the immunization of animals could lead to rapid and relatively inexpensive advances in public health. Opportunities for vaccine-based approaches to preventing zoonotic and emerging diseases that integrate veterinary and human medicine (the One Health paradigm) are emphasized.
Collapse
Affiliation(s)
- Thomas P Monath
- One Health Initiative Pro Bono Team, United States(1); Austria; PaxVax Inc., United States.
| |
Collapse
|
68
|
Possible future monoclonal antibody (mAb)-based therapy against arbovirus infections. BIOMED RESEARCH INTERNATIONAL 2013; 2013:838491. [PMID: 24058915 PMCID: PMC3766601 DOI: 10.1155/2013/838491] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2013] [Revised: 07/05/2013] [Accepted: 07/11/2013] [Indexed: 11/17/2022]
Abstract
More than 150 arboviruses belonging to different families are known to infect humans, causing endemic infections as well as epidemic outbreaks. Effective vaccines to limit the occurrence of some of these infections have been licensed, while for the others several new immunogens are under development mostly for their improvements concerning safety and effectiveness profiles. On the other hand, specific and effective antiviral drugs are not yet available, posing an urgent medical need in particular for emergency cases. Neutralizing monoclonal antibodies (mAbs) have been demonstrated to be effective in the treatment of several infectious diseases as well as in preliminary in vitro and in vivo models of arbovirus-related infections. Given their specific antiviral activity as well-tolerated molecules with limited side effects, mAbs could represent a new therapeutic approach for the development of an effective treatment, as well as useful tools in the study of the host-virus interplay and in the development of more effective immunogens. However, before their use as candidate therapeutics, possible hurdles (e.g., Ab-dependent enhancement of infection, occurrence of viral escape variants) must be carefully evaluated. In this review are described the main arboviruses infecting humans and candidate mAbs to be possibly used in a future passive immunotherapy.
Collapse
|
69
|
Carrera JP, Forrester N, Wang E, Vittor AY, Haddow AD, López-Vergès S, Abadía I, Castaño E, Sosa N, Báez C, Estripeaut D, Díaz Y, Beltrán D, Cisneros J, Cedeño HG, Travassos da Rosa AP, Hernandez H, Martínez-Torres AO, Tesh RB, Weaver SC. Eastern equine encephalitis in Latin America. N Engl J Med 2013; 369:732-44. [PMID: 23964935 PMCID: PMC3839813 DOI: 10.1056/nejmoa1212628] [Citation(s) in RCA: 76] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND The eastern equine encephalitis (EEE) and Venezuelan equine encephalitis (VEE) viruses are pathogens that infect humans and horses in the Americas. Outbreaks of neurologic disease in humans and horses were reported in Panama from May through early August 2010. METHODS We performed antibody assays and tests to detect viral RNA and isolate the viruses in serum samples from hospitalized patients. Additional cases were identified with enhanced surveillance. RESULTS A total of 19 patients were hospitalized for encephalitis. Among them, 7 had confirmed EEE, 3 had VEE, and 1 was infected with both viruses; 3 patients died, 1 of whom had confirmed VEE. The clinical findings for patients with EEE included brain lesions, seizures that evolved to status epilepticus, and neurologic sequelae. An additional 99 suspected or probable cases of alphavirus infection were detected during active surveillance. In total, 13 cases were confirmed as EEE, along with 11 cases of VEE and 1 case of dual infection. A total of 50 cases in horses were confirmed as EEE and 8 as VEE; mixed etiologic factors were associated with 11 cases in horses. Phylogenetic analyses of isolates from 2 cases of equine infection with the EEE virus and 1 case of human infection with the VEE virus indicated that the viruses were of enzootic lineages previously identified in Panama rather than new introductions. CONCLUSIONS Cases of EEE in humans in Latin America may be the result of ecologic changes that increased human contact with enzootic transmission cycles, genetic changes in EEE viral strains that resulted in increased human virulence, or an altered host range. (Funded by the National Institutes of Health and the Secretaría Nacional de Ciencia, Tecnología e Innovación, Panama.).
Collapse
MESH Headings
- Adolescent
- Animals
- Antibodies, Viral/blood
- Child
- Child, Preschool
- Disease Outbreaks
- Encephalitis Virus, Eastern Equine/genetics
- Encephalitis Virus, Eastern Equine/immunology
- Encephalitis Virus, Eastern Equine/isolation & purification
- Encephalitis Virus, Venezuelan Equine/genetics
- Encephalitis Virus, Venezuelan Equine/immunology
- Encephalitis Virus, Venezuelan Equine/isolation & purification
- Encephalomyelitis, Eastern Equine/epidemiology
- Encephalomyelitis, Eastern Equine/veterinary
- Encephalomyelitis, Venezuelan Equine/epidemiology
- Encephalomyelitis, Venezuelan Equine/veterinary
- Fatal Outcome
- Female
- Horse Diseases/epidemiology
- Horses
- Humans
- Infant
- Male
- Panama/epidemiology
- Phylogeny
- RNA, Viral/blood
Collapse
Affiliation(s)
- Jean-Paul Carrera
- Department of Research in Virology and Biotechnology, Gorgas Memorial Institute of Health Studies, Panama City, Panama
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
70
|
Guerbois M, Volkova E, Forrester NL, Rossi SL, Frolov I, Weaver SC. IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety. PLoS Negl Trop Dis 2013; 7:e2197. [PMID: 23675542 PMCID: PMC3649961 DOI: 10.1371/journal.pntd.0002197] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2012] [Accepted: 03/26/2013] [Indexed: 01/04/2023] Open
Abstract
The live-attenuated TC-83 strain is the only licensed veterinary vaccine available to protect equids against Venezuelan equine encephalitis virus (VEEV) and to protect humans indirectly by preventing equine amplification. However, TC-83 is reactogenic due to its reliance on only two attenuating point mutations and has infected mosquitoes following equine vaccination. To increase its stability and safety, a recombinant TC-83 was previously engineered by placing the expression of the viral structural proteins under the control of the Internal Ribosome Entry Site (IRES) of encephalomyocarditis virus (EMCV), which drives translation inefficiently in insect cells. However, this vaccine candidate was poorly immunogenic. Here we describe a second generation of the recombinant TC-83 in which the subgenomic promoter is maintained and only the capsid protein gene is translated from the IRES. This VEEV/IRES/C vaccine candidate did not infect mosquitoes, was stable in its attenuation phenotype after serial murine passages, and was more attenuated in newborn mice but still as protective as TC-83 against VEEV challenge. Thus, by using the IRES to modulate TC-83 capsid protein expression, we generated a vaccine candidate that combines efficient immunogenicity and efficacy with lower virulence and a reduced potential for spread in nature. Venezuelan equine encephalitis virus (VEEV) is transmitted by mosquitoes and widely distributed in Central and South America, causing regular outbreaks in horses and humans. Often misdiagnosed as dengue, VEEV infection in humans can lead to lifelong neurological sequelae and is fatal in up to >80% of equine cases, representing a significant socio-economic burden and constant public health threats for developing countries of Latin America. The only available vaccine, the live-attenuated TC-83 strain, is restricted to veterinary use due to its high reactogenicity in humans and risk for reversion to virulence, which could initiate an epidemic. By using an attenuation approach that allows the modulation of the virus capsid protein expression, we generated a new version of TC-83 that is more attenuated but still induces a protective immune response in mice. Additionally, this new vaccine cannot infect mosquitoes, which prevents the risk of spreading in nature. The attenuation approach we describe can be applied to a lot of other alphaviruses to develop vaccines against diseases regularly emerging and threatening developing countries.
Collapse
MESH Headings
- Aedes
- Animals
- Capsid Proteins/biosynthesis
- Capsid Proteins/genetics
- Cell Line
- Chlorocebus aethiops
- Disease Models, Animal
- Encephalitis Virus, Venezuelan Equine/genetics
- Encephalitis Virus, Venezuelan Equine/immunology
- Encephalitis Virus, Venezuelan Equine/pathogenicity
- Encephalomyelitis, Venezuelan Equine/immunology
- Encephalomyelitis, Venezuelan Equine/prevention & control
- Gene Expression
- Genomic Instability
- Humans
- Mice
- Protein Biosynthesis
- Survival Analysis
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/adverse effects
- Vaccines, Attenuated/genetics
- Vaccines, Attenuated/immunology
- Vaccines, Synthetic/administration & dosage
- Vaccines, Synthetic/adverse effects
- Vaccines, Synthetic/genetics
- Vaccines, Synthetic/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/adverse effects
- Viral Vaccines/genetics
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Mathilde Guerbois
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Eugenia Volkova
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Naomi L. Forrester
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Shannan L. Rossi
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Ilya Frolov
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
| | - Scott C. Weaver
- Institute for Human Infections and Immunity, Sealy Center for Vaccine Development, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America
- * E-mail:
| |
Collapse
|
71
|
Nurudeen SK, Grossman LC, Bourne L, Guarnaccia MM, Sauer MV, Douglas NC. Reproductive Outcomes of HIV Seropositive Women Treated by Assisted Reproduction. J Womens Health (Larchmt) 2013; 22:243-9. [DOI: 10.1089/jwh.2012.3855] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sahadat K. Nurudeen
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Lisa C. Grossman
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Lawton Bourne
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Michael M. Guarnaccia
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Mark V. Sauer
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| | - Nataki C. Douglas
- Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, College of Physicians and Surgeons, Columbia University, New York, New York
| |
Collapse
|
72
|
Adams AP, Navarro-Lopez R, Ramirez-Aguilar FJ, Lopez-Gonzalez I, Leal G, Flores-Mayorga JM, Travassos da Rosa APA, Saxton-Shaw KD, Singh AJ, Borland EM, Powers AM, Tesh RB, Weaver SC, Estrada-Franco JG. Venezuelan equine encephalitis virus activity in the Gulf Coast region of Mexico, 2003-2010. PLoS Negl Trop Dis 2012; 6:e1875. [PMID: 23133685 PMCID: PMC3486887 DOI: 10.1371/journal.pntd.0001875] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2012] [Accepted: 09/10/2012] [Indexed: 11/18/2022] Open
Abstract
Venezuelan equine encephalitis virus (VEEV) has been the causative agent for sporadic epidemics and equine epizootics throughout the Americas since the 1930s. In 1969, an outbreak of Venezuelan equine encephalitis (VEE) spread rapidly from Guatemala and through the Gulf Coast region of Mexico, reaching Texas in 1971. Since this outbreak, there have been very few studies to determine the northward extent of endemic VEEV in this region. This study reports the findings of serologic surveillance in the Gulf Coast region of Mexico from 2003–2010. Phylogenetic analysis was also performed on viral isolates from this region to determine whether there have been substantial genetic changes in VEEV since the 1960s. Based on the findings of this study, the Gulf Coast lineage of subtype IE VEEV continues to actively circulate in this region of Mexico and appears to be responsible for infection of humans and animals throughout this region, including the northern State of Tamaulipas, which borders Texas. Venezuelan equine encephalitis virus (VEEV) has been responsible for hundreds of thousands of human and equine cases of severe disease in the Americas. In 1969, an outbreak of Venezuelan equine encephalitis (VEE) spread rapidly from Guatemala and through the Gulf Coast region of Mexico, reaching Texas in 1971. Since this outbreak, there has been very little done to understand the ecology of VEEV in this region. Here, we present that the results of recent field studies that focus on confirming the continued existence of enzootic VEEV in the Gulf Coast region of Mexico. We performed serological analyses of sera collected between 2003 and 2010 from humans, cattle, horses, and dogs in various regions along the Gulf Coast of Mexico, and these data were complemented by wildcaught rodent serosurveys. Additionally, phylogenetic analyses were performed on VEEV isolates from this region to determine whether there have been substantial genetic changes in these viruses since the 1960s.
Collapse
Affiliation(s)
- A Paige Adams
- Institute for Human Infections and Immunity, Center for Tropical Diseases, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas, United States of America.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
73
|
Weaver SC, Winegar R, Manger ID, Forrester NL. Alphaviruses: population genetics and determinants of emergence. Antiviral Res 2012; 94:242-57. [PMID: 22522323 DOI: 10.1016/j.antiviral.2012.04.002] [Citation(s) in RCA: 113] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2011] [Revised: 04/05/2012] [Accepted: 04/07/2012] [Indexed: 12/28/2022]
Abstract
Alphaviruses are responsible for several medically important emerging diseases and are also significant veterinary pathogens. Due to the aerosol infectivity of some alphaviruses and their ability to cause severe, sometimes fatal neurologic diseases, they are also of biodefense importance. This review discusses the ecology, epidemiology and molecular virology of the alphaviruses, then focuses on three of the most important members of the genus: Venezuelan and eastern equine encephalitis and chikungunya viruses, with emphasis on their genetics and emergence mechanisms, and how current knowledge as well as gaps influence our ability to detect and determine the source of both natural outbreaks and potential use for bioterrorism. This article is one of a series in Antiviral Research on the genetic diversity of emerging viruses.
Collapse
Affiliation(s)
- Scott C Weaver
- Institute for Human Infections and Immunity and Department of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
| | | | | | | |
Collapse
|
74
|
Abstract
Genetic and biological characterization of new hepaciviruses infecting animals contributes to our understanding of the ultimate origins of hepatitis C virus (HCV) infection in humans and dramatically enhances our ability to study its pathogenesis using tractable animal models. Animal homologs of HCV include a recently discovered canine hepacivirus (CHV) and GB virus B (GBV-B), both viruses with largely undetermined natural host ranges. Here we used a versatile serology-based approach to determine the natural host of the only known nonprimate hepacivirus (NPHV), CHV, which is also the closest phylogenetic relative of HCV. Recombinant protein expressed from the helicase domain of CHV NS3 was used as antigen in the luciferase immunoprecipitation system (LIPS) assay to screen several nonprimate animal species. Thirty-six samples from 103 horses were immunoreactive, and viral genomic RNA was present in 8 of the 36 seropositive animals and none of the seronegative animals. Complete genome sequences of these 8 genetically diverse NPHVs showed 14% (range, 6.4% to 17.2%) nucleotide sequence divergence, with most changes occurring at synonymous sites. RNA secondary structure prediction of the 383-base 5' untranslated region of NPHV was refined and extended through mapping of polymorphic sites to unpaired regions or (semi)covariant pairings. Similar approaches were adopted to delineate extensive RNA secondary structures in the coding region of the genome, predicted to form 27 regularly spaced, thermodynamically stable stem-loops. Together, these findings suggest a promising new nonprimate animal model and provide a database that will aid creation of functional NPHV cDNA clones and other novel tools for hepacivirus studies.
Collapse
|